Back to search
Secondary Angiosarcoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Secondary Angiosarcoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Secondary Angiosarcoma trials you may qualify forAGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various d…
This study will enroll patients with specific subtypes of unresectable or metastatic soft tissue sarcoma, and will combine tislelizumab with the standard chemot…
Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (adv…
Cutaneous angiosarcoma is a rare cancer for which effective treatment has not been developed sufficiently. Still, because it often occurs in elderly people, the…
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipil…
This phase II trial investigates how well oleclumab and durvalumab work in treating patients with sarcoma that has come back (recurrent) or does not respond to…
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a nove…